Dudum Andrew

HIMS CEO Dudum Andrew sold 175.7K shares for $11.0M across 9 transactions on 2025-10-16, reducing holdings 65.5% to 92.5K shares.

CEO Dudum Andrew executed 9 separate sales totaling 175,661 shares for $11,029,998.78 on 2025-10-16 at prices ranging from $62.65 to $63.49, with a blended average of $62.79. This represents a -65.5% reduction in his shareholdings from 268,184 to 92,523 shares. The transaction occurred when the stock was trading near its 52-week high ($68.74), though the current price has since declined to $51.36 (-25.3% from the 52-week high and -11.2% over 30 days). His prior 5 trades at HIMS show mixed outcomes: one prior sale (2025-09-17) saw a 30-day decline of -1.6%, while the other 4 recent sales (2025-09-16) each posted 30-day gains ranging from +9.1% to +11.8%. His cross-ticker track record spans 20 prior sells with a 90-day well-timed rate of 0.00%, indicating limited historical predictive value regarding subsequent price direction. The magnitude of this liquidation—nearly two-thirds of his position—merits investor attention given the CEO's material reduction in skin-in-the-game during a period when the stock has subsequently faced downward pressure.

CEO Andrew Dudum sold 65,110 shares of HIMS at $50.57, reducing stake by 40.6% to 95,315 shares; stock now trades at $57.82

CEO Andrew Dudum sold 65,110 shares (65.1K shares) on 2025-09-17 at $50.57, a substantial 40.6% reduction in his holdings from 160,425 shares to 95,315 shares. The $3,292,905.70 ($3.3M) transaction occurred at a price $7.25 below the current market price of $57.82, representing a notable gap between execution and present valuation. Dudum executed five consecutive sales on 2025-09-16, followed by this single sale on 2025-09-17, suggesting a deliberate liquidation pattern rather than isolated activity. While his cross-ticker track record shows 20 prior sells with an average 30-day return of +1.6%, timing cannot be assessed on this specific transaction given the absence of post-transaction outcome data, and his prior activity at HIMS has not yet produced measurable 30 or 90-day returns to establish a pattern at this ticker.

CEO Andrew Dudum sells 175,661 shares at $53.42 avg ($9.4M), reducing holdings by 52.3% on single day at 52-week highs.

CEO Andrew Dudum executed 9 separate sales on 2025-09-16 totaling 175,661 shares for $9,384,625.38, reducing his holdings from 336,086 shares to 160,425 shares—a 52.3% reduction. The sales occurred at prices ranging from $52.90 to $54.21 (blended average $53.42), near the 52-week high of $68.74 and well above the current price of $50.35. His cross-ticker track record shows a 90-day well-timed rate of 100.00% across 20 prior sells, though at HIMS specifically, prior measurable outcomes show positive 30-day returns (August trades at +11.6% to +12.0%), suggesting recent strength in the stock. The magnitude and concentrated timing of this liquidation—eliminating more than half his position in a single trading session—represents a significant reduction in his direct financial alignment with the company, which warrants attention given the CEO's elevated visibility and influence on firm direction.

CEO Dudum Andrew sold 175,661 shares for $7,914,734.62 on 2025-08-18, cutting holdings by -66.2%

On 2025-08-18, CEO Dudum Andrew executed 6 separate sales totaling 175,661 shares for $7,914,734.62 at a blended average price of $45.06, reducing his holdings from 265,182 shares to 89,521 shares (a -66.2% reduction). The stock has since declined significantly: the current price of $43.38 is -36.9% from the 52-week high of $68.74, with 30-day performance at -8.9% and 90-day performance at -19.0%. His cross-ticker track record shows a 100% well-timed rate on prior sells with an average 90-day return of -19.6%, suggesting a consistent pattern of selling before declines. However, his same-ticker history at HIMS shows 5 prior sales in July–August 2025, all with negative 30-day returns ranging from -12.2% to -12.5%, but with 90-day outcomes not yet measurable. The substantial scale of this disposition—nearly two-thirds of his pre-transaction holdings in a single filing—alongside deteriorating price action and his demonstrated track record of well-timed exits warrants close attention to potential forward guidance or operational signals.

CEO Dudum Andrew sold 660,000 HIMS shares at $50.58 (Aug 7); 23% of holdings; stock now $49.98, -27.3% from 52-week high.

CEO Andrew Dudum sold 660,000 shares (660.0K shares) valued at $33,384,120.00 on 2025-08-07, reducing his stake from 2.87M to 2.21M shares. The sale occurred near the stock's recent range but at a significant discount to the 52-week high of $68.74; the stock has declined 21.9% over the past 90 days. This represents Dudum's fifth sell at HIMS in the past month (with sales also on 2025-07-21 and 2025-07-16), following a broader pattern of 20 prior cross-ticker sales across his transaction history, which have averaged a -8.5% 30-day return. The company's fundamentals remain strong (annual revenue growth of +69.3%, $42.5M net income on $544.8M quarterly revenue), but the elevated P/E of 86.17 and the concentrated selling sequence warrant attention to whether the CEO's dispositions reflect valuation concerns or liquidity needs unrelated to operational conviction.

CEO Dudum Andrew sells 125,335 shares ($6.2M) across 4 transactions at blended average $49.54 on 2025-07-21; retains 92.3K shares post-sale.

Andrew Dudum, the CEO, executed 4 separate sales totaling 125,335 shares for $6,208,636.66 at an average price of $49.54 on a single date (2025-07-21), representing a -57.6% reduction in his holdings from 217,648 shares to 92,313 shares. The transaction occurs as HIMS stock is up +38.2% over the prior 30 days and +106.2% over 90 days, trading at $58.02 (currently 15.6% below the 52-week high of $68.74). The company reported strong fundamentals with $586.0M revenue in the latest quarter, $49.5M net income, and +69.3% annual revenue growth, though the stock trades at an elevated P/E of 100.03. His prior sales at HIMS have shown mixed timing outcomes—recent sales on 2025-06-17 showed negative 30-day returns of -14.6% and -15.9%, though the 90-day outcomes remain unmeasurable. This large, concentrated liquidation by the CEO warrants investor scrutiny given the magnitude of the position reduction and the significant appreciation preceding the sales.

CEO Dudum Andrew sold 50,326 shares for $2,530,034.04 across 3 transactions at blended $50.27, reducing stake 20.9%

CEO Dudum Andrew executed 3 separate sales totaling 50,326 shares for $2,530,034.04 on 2025-07-16 at prices ranging from $50.24 to $50.82 (blended average $50.27), reducing his post-transaction holdings to 190,126 shares from 240,452 shares. The stock is currently trading at $50.38, down 17.5% over 30 days and 26.7% below its 52-week high of $68.74, suggesting the transactions occurred near recent trading levels. His prior trades at HIMS have generated negative 30-day returns (-14.6%, -15.9%, -8.9%, -8.9%, -8.0%), although outcomes are still pending at the 90-day mark. The company shows strong fundamentals with annual revenue growth of 69.3% and net income of $49,485,000.00, though the P/E of 86.86 reflects elevated valuation expectations relative to earnings. This sale represents a material reduction of his equity stake and warrants investor monitoring, particularly given the timing relative to recent stock weakness.

CEO Dudum sold 240,771 shares for $13.8M across 8 transactions; holdings fell 71.7% to 95,105 shares

Andrew Dudum executed 8 separate sales totaling 240,771 shares for $13,813,792.10 between June 16–17, 2025, at prices ranging from $56.35 to $59.45, with a blended average price of $57.37. The sale reduces his HIMS holdings from 335,876 to 95,105 shares—a 71.7% reduction. This magnitude is material for a CEO and notably follows five prior sales at HIMS in May 2025, all of which declined 4–6% in the 30 days following sale. His cross-ticker track record shows an average 90-day return of +69.6% after prior sells (meaning the stock rose, making those sales poorly timed), though his 90-day well-timed rate at HIMS remains 0%. The company's fundamentals remain robust—latest quarterly revenue of $586,010,000.00, net income of $49,485,000.00, and annual revenue growth of +69.3%—yet HIMS is down 8.4% over 30 days and trades 13.8% below its 52-week high. The concentration and scale of this transaction warrant investor attention to CEO confidence signals relative to recent price weakness.

Hims CEO sold 175,661 shares (175.7K) for $10,251,387.70 across 7 transactions on 2025-05-16, reducing holdings by 66.3%

Dudum Andrew, CEO of Hims & Hers Health, Inc., executed 7 separate sales totaling 175,661 shares for $10,251,387.70 at prices ranging from $57.84 to $59.27 (blended average $58.36). This represented a significant portfolio reduction, cutting his holdings from 264,972 shares to 89,311 shares—a 66.3% reduction. The timing coincides with strong recent stock performance: the 30-day return is +128.9%, and the stock is currently trading at $62.34, above all transaction prices. His prior sales at HIMS have generated outsized positive 30-day returns (+130.7%, +129.0%, +128.4% on recent April 16 transactions), indicating these recent sales occurred during a sustained momentum rally. The company itself shows strong fundamentals with annual revenue growth of +69.3%, though the P/E of 107.48 reflects elevated valuation relative to earnings.

HIMS CEO Dudum sold 91,667 shares for $3,077,070.06 (blended avg $33.57); cut stake by -49.9% over 2 days.

Andrew Dudum, CEO of Hims & Hers Health, Inc. (HIMS), executed 2 separate sales totaling 91,667 shares for $3,077,070.06 on 2025-04-28 and 2025-04-29, reducing his holdings from 183,770 shares to 92,103 shares (a -49.9% reduction). The blended average price of $33.57 compares to the current price of $33.10 and sits well below the 52-week high of $68.74. Dudum's cross-ticker track record shows 20 prior sells with an average 30-day return of -29.7%, indicating a pattern of selling into declines; his prior trades at HIMS show mixed timing outcomes (two recent sells on 2025-04-16 have no measurable outcome yet, while earlier March sales showed 30-day declines of -19.3% and -20.2%). The company's fundamentals remain solid—$401.6M quarterly revenue with +69.3% annual growth and $75.6M net income—suggesting the sales reflect portfolio management rather than a fundamental deterioration signal.